New targets on molecular target therapy of triple negative breast cancer
10.3760/cma.j.issn.1673-4203.2014.11.014
- VernacularTitle:三阴性乳腺癌分子靶向治疗研究进展
- Author:
Xianghou XIA
;
Hongjian YANG
- Publication Type:Journal Article
- Keywords:
TNBC;
Molecular targeted therapy;
Bevacimab;
Rituximab;
PARP;
Recurrence;
Neoplasm metastasis
- From:
International Journal of Surgery
2014;41(11):766-769
- CountryChina
- Language:Chinese
-
Abstract:
Triple negative breast cancer (TNBC) is characterized by lack of expression of the estrogen (ER)and progesterone receptors (PRs) and the human epidermal growth factor receptor (HER-2) that are commonly observed in other breast cancer subtypes.Treatment options are limited since the hormonal receptor and HER-2 antagonists are ineffective for TNBC.In contrast to non-TNBC,TNBC is more aggressive with higher recurrence,metastatic,and mortality rates.Besides further studies on cytotoxic drugs and chemotherapy regimens,More studies on potential targeted molecular treatment of TNBC should be strengthened.For the moment,potential targeted molecular treatment of TNBC including antiangiogenic agents,epidermal growth factor receptor (EGFR) inhibitors and poly (adenosine diphosphate ribose) polymerase (PARP).In contrast to their surprising anti-tumor effectivness in basic experiments,these targeted molecular agents show no promising results in clinical trials by now.This article aims to review advancements of targeted molecular treatment of TNBC in recent years.
